New NSCLC standard of care? Perioperative immunotherapy trial improves outcomes
The addition of perioperative durvalumab leads to greater event-free survival and pathological response than neoadjuvant chemotherapy alone, study shows.
Perioperative durvalumab in combination with chemotherapy should be considered as a potential new treatment option for resectable non-small cell lung cancer, according to US oncologists.
Results from their phase III randomised trial suggest that the addition of perioperative immunotherapy with durvalumab leads to greater event-free survival and pathological response than neoadjuvant chemotherapy alone.
